[MCTD--mixed connective tissue disease]

Area of Science:

• Rheumatology
• Immunology
• Genetics

Context:

• Mixed connective tissue disease (MCTD) is defined by overlapping clinical and serological features of systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and polymyositis/dermatomyositis (PM/DM).
• Diagnostic criteria often involve high titers of anti-U1RNP antibodies and specific clinical manifestations.
• The nosological status of MCTD as a distinct entity remains a subject of ongoing debate within the medical community.

Purpose:

• To delineate the characteristics, diagnostic challenges, and clinical progression of Mixed Connective Tissue Disease (MCTD).
• To review current understanding of MCTD pathogenesis, including genetic and potential infectious triggers.
• To summarize therapeutic strategies and prognostic factors associated with MCTD.

Summary:

• MCTD exhibits features of multiple autoimmune diseases, with diagnostic criteria including anti-U1RNP antibodies and specific clinical signs like hand edema, synovitis, myositis, Raynaud phenomenon, and acrosclerosis.
• Pathogenesis is thought to involve genetic predisposition and possibly viral infections.
• A significant proportion of patients transition to definite lupus erythematosus (LE) or systemic sclerosis (SSc), highlighting the dynamic nature of the disease. Therapeutic approaches involve glucocorticoids, immunosuppressants, and endothelin receptor antagonists, though robust clinical trial data is limited.

Impact:

• Understanding MCTD's complex presentation and progression is crucial for accurate diagnosis and management of patients with overlapping autoimmune conditions.
• Clarifying MCTD's distinctiveness impacts disease classification and research focus.
• Improved management strategies can mitigate risks of severe complications like pulmonary hypertension and cardiac failure, potentially improving patient outcomes.